An estimated 3 million people in the US suffer from Opioid Use Disorder (OUD). OUD and addiction, in general, are notoriously difficult to treat, with most current treatments inadequately addressing patients’ symptoms, and often leading to relapse. At atai, we are committed to pioneering new treatment options for those suffering from the most challenging mental health conditions. We’re conducting a clinical program with ibogaine, IBX-210, for the treatment of OUD. Ibogaine has shown promising potential in reducing opioid cravings and supporting withdrawal symptoms in previous clinical studies. You can follow the progress of this program and our other clinical programs by visiting our website and signing up for email updates. https://atai.life/ Special thanks to Heather McKenzie at BioSpace for raising this important topic and covering our research. Read more: https://lnkd.in/eVMb-e7i #Ibogaine #OpioidCrisis #AddictionTreatment #MentalHealth
atai Life Sciences’ Post
More Relevant Posts
-
Thanks to The New York Times for including us in today's piece about ibogaine as a potential treatment for opioid addiction. The article explores a number of important points, including: - The devastating impact of opioid addiction in the US today, with overdose deaths exceeding 100,000 a year, as well as the human stories behind the numbers - the harsh and devastating realities faced by those who suffer. - The need for new treatments beyond those that currently exist for opioid use disorder, which most patients stop taking after six months. - The results of an ibogaine study published in Nature earlier this year which found that military veterans with traumatic brain injuries who underwent a single ibogaine therapy session experienced marked improvements in disability, psychiatric symptoms and cognition. - The science behind how ibogaine is believed to work in the brain, with commentary from Deborah C. Mash and Gül Dölen. - The incredible policy work being done in some states, such as that of Bryan Hubbard in Ohio who is pushing for state funding for ibogaine research. Grateful to Andrew Jacobs for raising awareness of the potential of ibogaine to address one of the biggest mental health crises in the US today. https://lnkd.in/epJFW4ht #ibogaine #psychedelics #mentalhealth #addictionrecovery
Powerful Psychedelic Gains Renewed Attention as a Treatment for Opioid Addiction
https://www.nytimes.com
To view or add a comment, sign in
-
Healthcare Leader | Behavioral Health Patient Navigator | Family Interventionist | Recovery Advocate
Read an eye-opening piece in The New York Times by Maia Szalavitz on the challenges of managing pain in recovery. It's a personal and profound exploration of addiction, revealing how untreated pain can actually trigger relapse. It's clear that we need to understand more about how opioids interact with recovery and addiction. We must prioritize patient-centered care, balancing pain relief with the risks of addiction. Worth a read! https://nyti.ms/3u4tPrg #addictionrecovery #painmanagement
Opinion | After My Heroin Addiction, Would Pain Medicine Set Me Back?
https://www.nytimes.com
To view or add a comment, sign in
-
A Closer Look at Methadone’s Role in Addiction Treatment - If you are prescribed methadone for the sake of enhancing your recovery, it is important to understand your medication, including how it works and the potential side effects of methadone. Learn more! https://bit.ly/3uDoWWl
A Closer Look at Methadone’s Role in Addiction Treatment
https://www.pyramid-healthcare.com
To view or add a comment, sign in
-
U.S. overdose death rate: now worse from stimulants than from opioids! Time for states & payers to cover the standard of care. Not doing so is simply stigma — & should not be tolerated! #addiction #addictiontreatment #addictionrecovery #substanceusedisorder #asam #nida #drugabuse #drugpolicy #qotd #harmreductionsaveslives #shatterproof #sud #oud #mat #evidencebasedpractice #recoveryispossible #overdoseprevention #overdoseawareness #harmreduction #drugaddiction #alcoholaddiction #alcoholism #ONDCP #substanceabuse #samhsa #csat #publichealth #publichealthmatters #drugaddiction #pear #reset
DynamiCare Health provides a comprehensive behavioral health approach known as Contingency Management for the treatment of Stimulant Use Disorder (StUD), which is consistent with the current standard of care as described in the American Society of Addiction Medicine - ASAM guidelines. CM also offers a cost effective solution to treatment leading to a value-based solution for payers. We were thrilled to sit down with Kelley Bowker, CEO of DynamiCare, to hear the latest: https://lnkd.in/gy8w4SYF #substanceuse #contingencymanagement
Closing Gaps in Treatment Networks for Stimulant Addictions
behavioralhealthtech.com
To view or add a comment, sign in
-
A lot of research has gone into ketamine in recent years. Once seen as little more than a dissociative anesthetic, it is now increasingly being used in mental health treatment. Many confuse ketamine with other drugs, and some wonder, is ketamine an opioid? Ketamine is not an opioid – however, it does interact with opioids and the brain's opioid receptors in surprising ways. To learn more about the Effects of Ketamine, visit https://lnkd.in/gz-4mJRJ. If you or a loved one are struggling with ketamine addiction, we are here to help every step of the way. Call us at 888.348.2835 to discover personalized treatment options tailored to your needs. . . . #addictionrecovery #addictionhelp #addictionawareness #recovery #sobriety #odaat #wedorecover
Is Ketamine an Opioid? | Addiction Treatment Center | Rehab
https://www.scbh.com
To view or add a comment, sign in
-
The results of our recent survey, conducted by The Harris Poll, focus on the behaviors and attitudes of #OlderAdults surrounding #Alcohol, #Marijuana and #MentalHealth. As we continuously strive to understand the evolving landscape of substance use and mental health, this survey provides critical insights that could reshape approaches to treating the aging population. Learn more here: https://bit.ly/3T9NTRJ
Doctors Don't Discuss Alcohol Drug Use with Older Adult Patients
caron.org
To view or add a comment, sign in
-
Addressing Dual Diagnosis in the Opioid Epidemic: A Professional Perspective The opioid crisis has escalated with the emergence of 'legal' opiates like kratom and tianeptine. In 2021, the US saw a significant rise in overdose deaths, many involving these substances. A crucial aspect for mental health professionals is the prevalence of dual diagnosis – the coexistence of substance abuse and mental health disorders. The challenge lies in treating the intertwined nature of addiction and psychiatric conditions. Opioids often mask underlying mental health issues, leading to complex treatment scenarios. At Viewpoint Dual Recovery Center in Prescott, AZ, a multidisciplinary approach is adopted, integrating addiction treatment with mental health care. Their evidence-based therapies and psychiatric interventions offer a comprehensive model for treating individuals with co-occurring disorders. 🔗 Explore the intricacies of dual diagnosis and Viewpoint's approach in our detailed blog post: https://lnkd.in/gyMRCQbx #MentalHealthProfessionals #DualDiagnosisTreatment #OpioidCrisis "If you're a mental health practitioner, join the discussion on best practices for dual diagnosis treatment. Your insights are valuable."
Combatting the Opioid Crisis: Unveiling the Dual Diagnosis Challenge
https://www.viewpointdualrecovery.com
To view or add a comment, sign in
-
Opioid addiction affects between 2 and 4 percent of the adult and adolescent population, despite a 2016 study showing around 70 percent of adults have been exposed to medical opioids. Risk factors for addiction can be biological, psychological, sociological and financial. Despite these complicated and overlapping factors, on top of limited data availability, there are already commercially-available AI models being used to predict addiction risk. MIT Jameel Clinic - AI & Health PI Marzyeh Ghassemi recently spoke with The New York Times Opinion Contributor Maia Szalavitz on the risks that could accompany a new wave of AI models being used to predict addiction risk. Read: https://lnkd.in/ekkx-pqU #aiforgood #aiforhealth #aibias #aifairness #aisafety
Opinion | Say Hello to Your Addiction Risk Score — Courtesy of the Tech Industry
https://www.nytimes.com
To view or add a comment, sign in
-
Read an eye-opening piece in The New York Times by Maia Szalavitz on the challenges of managing pain in recovery. It's a personal and profound exploration of addiction, revealing how untreated pain can actually trigger relapse. It's clear that we need to understand more about how opioids interact with recovery and addiction. We must prioritize patient-centered care, balancing pain relief with the risks of addiction. Worth a read! https://nyti.ms/3u4tPrg #addictionrecovery #painmanagement
Opinion | After My Heroin Addiction, Would Pain Medicine Set Me Back?
https://www.nytimes.com
To view or add a comment, sign in
-
Discover the journey to healing after benzo addiction in our comprehensive guide. Gain insights into the effects of benzodiazepines on the brain, find support for recovery, and access essential resources. #BenzodiazepineAddiction #HealingJourney #RecoveryGuide https://loom.ly/R_0M68o
Brain Healing After Benzos: A Comprehensive Guide - Calusa Recovery
https://calusarecovery.com
To view or add a comment, sign in
More from this author
-
Data from our novel EGX series shows translational antidepressant-like effects, similar to those seen with psilocybin
atai Life Sciences 8mo -
Meet the Faces of atai: Patrick Deasey (US)
atai Life Sciences 8mo -
Behind the Scenes with Krissty Sumida: Navigating the Intricate Pathways of Mental Health Research
atai Life Sciences 9mo
CEO & Founder Evithé Biotechnology
1moGood to see the Ibogaine research move forward. Is the Radboud University still involved in this work these days?